Surender Kumar

 

I was a human resources executive in a leading thermal power generation company in India.

During a blood donation camp in 2010, I found out that I have hepatitis B. I had never heard about hepatitis B before this incident. It was a shocking moment for me because I had never had a blood transfusion. I discussed with family and prepared all of them for hepatitis B screening.

The results were a shock to all of us as three family members were also diagnosed with hepatitis B. It had been passed on to us from our mothers at birth.

I decided to leave my job which was the only source of income for me and my family, and I started education programmes about the diseases in the most vulnerable slums and villages in India.

Being a survivor, it is now my duty to protect future generations. I started my organisation RANN Foundation, which works for awareness and prevention of viral hepatitis in India. I never hide my hepatitis B positive status; in fact I share my story whenever I can but I know that not everyone who is living with hepatitis can reveal their status due to discrimination in the family and society. Misconceptions and stigma attached to the disease often lead to discrimination and marginalisation of people living with the chronic infection, which is a major concern and has a big impact on the lives of patients in India.

My fight against the disease focuses on multiple fronts: preventing hepatitis B through vaccination camps for children who have dropped out of school, conducting education programmes on viral hepatitis in schools and urban slums, and providing psychosocial support to patients. With around 1.5 lakh (150,000) deaths annually and almost 60 million Indians affected, viral hepatitis continues to be a serious public health concern.

Share your story now

For people living with a hepatitis condition, it really helps to know they’re not alone. If you are interested in sharing your story, email us to find out more.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close